Your browser doesn't support javascript.
loading
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
Alton, Eric W F W; Beekman, Jeffery M; Boyd, A Christopher; Brand, June; Carlon, Marianne S; Connolly, Mary M; Chan, Mario; Conlon, Sinead; Davidson, Heather E; Davies, Jane C; Davies, Lee A; Dekkers, Johanna F; Doherty, Ann; Gea-Sorli, Sabrina; Gill, Deborah R; Griesenbach, Uta; Hasegawa, Mamoru; Higgins, Tracy E; Hironaka, Takashi; Hyndman, Laura; McLachlan, Gerry; Inoue, Makoto; Hyde, Stephen C; Innes, J Alastair; Maher, Toby M; Moran, Caroline; Meng, Cuixiang; Paul-Smith, Michael C; Pringle, Ian A; Pytel, Kamila M; Rodriguez-Martinez, Andrea; Schmidt, Alexander C; Stevenson, Barbara J; Sumner-Jones, Stephanie G; Toshner, Richard; Tsugumine, Shu; Wasowicz, Marguerite W; Zhu, Jie.
Afiliação
  • Alton EW; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Beekman JM; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Boyd AC; Department of Pediatric Pulmonology, Laboratory of Translational Immunology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, The Netherlands.
  • Brand J; Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK.
  • Carlon MS; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Connolly MM; Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK.
  • Chan M; Lung Pathology Unit, Department of Airway Disease Infection, NHLI, Imperial College London, London, UK.
  • Conlon S; Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Brussels, Belgium.
  • Davidson HE; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Davies JC; Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford, UK.
  • Davies LA; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Dekkers JF; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Doherty A; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Gea-Sorli S; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Gill DR; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Griesenbach U; Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK.
  • Hasegawa M; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Higgins TE; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Hironaka T; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Hyndman L; Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford, UK.
  • McLachlan G; Department of Pediatric Pulmonology, Laboratory of Translational Immunology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, The Netherlands.
  • Inoue M; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Hyde SC; Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK.
  • Innes JA; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Maher TM; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Moran C; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Meng C; Gene Medicine Research Group, NDCLS, John Radcliffe Hospital, Oxford, UK.
  • Paul-Smith MC; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Pringle IA; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Pytel KM; ID Pharme Co. Ltd. (DNAVEC Center), Tsukuba, Japan.
  • Rodriguez-Martinez A; Department of Gene Therapy, National Heart and Lung Institute, Imperial College London, London, UK.
  • Schmidt AC; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Stevenson BJ; ID Pharme Co. Ltd. (DNAVEC Center), Tsukuba, Japan.
  • Sumner-Jones SG; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Toshner R; Centre for Genomic and Experimental Medicine, IGMM, University of Edinburgh, Edinburgh, UK.
  • Tsugumine S; UK Cystic Fibrosis Gene Therapy Consortium, Oxford, UK.
  • Wasowicz MW; Roslin Institute & R(D)SVS, University of Edinburgh, Midlothian, UK.
  • Zhu J; ID Pharme Co. Ltd. (DNAVEC Center), Tsukuba, Japan.
Thorax ; 72(2): 137-147, 2017 02.
Article em En | MEDLINE | ID: mdl-27852956
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Lentivirus / Fibrose Cística Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Thorax Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Lentivirus / Fibrose Cística Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Thorax Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Reino Unido